Skin
For the control of pruritus caused by allergic dermatitis and atopic dermatitis in dogs.
Active ingredient
Oclacitinib Maleate
Appearance
This product is a light brown or brown, cross-scored tablet.
Dosage and Administration
Calculated as oclacitinib. Oral administration: For dogs, 0.4 ～ 0.6 mg per 1 kg of body weight, twice a day for 14 consecutive days, and then once a day for maintenance therapy.
|
Body Weight Range (kg) |
Dosage (Tablet) |
||
|
3.6mg/Tablet |
5.4mg/Tablet |
16mg /Tablet |
|
|
3.0～4.4 |
0.5 |
- |
- |
|
4.5～5.9 |
- |
0.5 |
- |
|
6.0～8.9 |
1 |
- |
- |
|
9.0～13.4 |
- |
1 |
- |
|
13.5～19.9 |
- |
- |
0.5 |
|
20.0～26.9 |
- |
2 |
- |
|
27.0～39.9 |
- |
- |
1 |
|
40.0～54.9 |
- |
- |
1.5 |
|
55.0～80.0 |
- |
- |
2 |
Withdrawal Period
Not applicable.
Strength
Calculated as C15H23N5O2S: (1) 3.6mg; (2) 5.4mg; (3) 16mg
Pack size
1.2g/tables 30tablets/bottle
Storage
Store at 20 ～ 25°C, transportable at 15 ～ 40°C.
Shelf life
24 months
Oclacitinib is a synthetic intracellular non-receptor tyrosine kinase (Janus kinase, JAK for short) inhibitor. It inhibits the function of a variety of pruritogenic cytokines and pro-inflammatory cytokines, as well as cytokines involved in allergy that are dependent on JAK1 or JAK3 enzyme activity. It has little effect on cytokines involved in hematopoiesis that are dependent on JAK2.
After oral administration to dogs, the drug is absorbed rapidly and well. The feeding status of dogs has no significant effect on the absorption rate or extent.
Following intravenous and oral administration, the terminal half-life appeared similar with absolute bioavailability of 89%, and with low plasma protein binding rate of 66.3%~69.7%. Oclacitinib is metabolized in the dog to multiple metabolites and one major oxidative metabolite was identified in plasma and urine. Overall the major clearance route is metabolism with minor contributions from renal and biliary elimination.
This drug is not a corticosteroid or an antihistamine. The combined use of this product with glucocorticoids, cyclosporine, or other systemic immunosuppressants has not been evaluated.
1.For use in dogs aged 12 months or older only. Do not use in dogs younger than 12 months old or with a body weight of less than 3 kg. Do not use in breeding dogs, pregnant or lactating bitches. Do not use in dogs with severe infections.
2.Can be administered with food or on an empty stomach.
3.Monitor the development of infections (including demodicosis and tumors) in dogs using this product.
4.After handling the tablets, wash hands immediately. If the drug comes into contact with the eyes, rinse with water or normal saline immediately for at least 15 minutes, then seek medical attention.
5.Keep this product out of the reach of children.
6.In case of accidental ingestion by humans, seek medical attention immediately and inform the doctor of the relevant details.
